New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:31 EDTWEST, RIBT, ENVI, RST, NNVC, MSEX, ANFC, DNR, ARCP, BRX, DRRX, NJRThe Wall Street Forum to hold a conference
25th Annual Investment Conference to be held in New York on June 19.
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
18:44 EDTRSTOn The Fly: After Hours Movers
Subscribe for More Information
17:52 EDTRSTRosetta Stone strength attributed to report of private equity bid
The after-hours move higher in shares of Rosetta Stone is being attributed to a story from Mergermarket which said a group of private equity offered to purchase Rosetta Stone for between $9-$10 per share. Shares of Rosetta Stone are up $1.57, or 24.42%, to $8.00 in after-hours trading.
16:16 EDTENVIEnvivio reports Q1 adjusted EPS (2c), one estimate (4c)
Subscribe for More Information
May 21, 2015
07:25 EDTDNRUBS to hold a conference
Subscribe for More Information
May 20, 2015
08:33 EDTRIBTRiceBran receives additional R$1.2M arbitration award
Subscribe for More Information
May 18, 2015
08:31 EDTDRRXDURECT announces positive results from DUR-928 Phase 1 study
DURECT announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity, which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. It may also play an important role in protecting against acute kidney injury and other types of acute organ injury. This Phase 1 trial was a single-site, randomized, double-blinded, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of DUR-928 when orally administered once daily for 5 consecutive days to healthy volunteers. The 20-subject study evaluated DUR-928 in 2 consecutive 10-subject cohorts, the first receiving DUR-928 at a lower dose and the second at a higher dose. Following multiple dosing, DUR-928 was well-tolerated at both dose levels, with no clinically significant changes in vital signs, laboratory values or ECG parameters, no severe or serious drug-related adverse events reported and no subjects withdrawing from the study. Peak plasma concentrations achieved were at least 100-fold higher than endogenous levels, no accumulation in plasma concentrations were observed with repeat dosing, and dose related increases in plasma concentrations were observed with peak plasma concentration at approximately 2 6 hours after dosing.
May 15, 2015
16:28 EDTARCPAppaloosa Management gives quarterly update on stakes
Subscribe for More Information
May 14, 2015
08:50 EDTBRXBofA/Merrill U.S. REITs analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use